Asylia Diagnostics

Asylia Diagnostics is a diagnostics technology platform intended to provide safer immunotherapy for cancer patients. We collect molecular and real-world evidence data from patients treated with investigational drugs in clinical trials and patients treated by the standard of care. We then use our data platform and AI-powered technology to transform these highly heterogeneous patient populations into well-defined subgroups that share common molecular and immuno-pathophysiology profiles. By doing this, we are able to identify highly specific biomarkers and novel drug targets. We then use discovered endotypes, biomarkers, and drug targets to develop patient stratification, enrichment, and indication expansion strategies, early hits/leads for the therapeutic pipeline, and eventually complex theranostic products together with our biopharma and IVD partners.

Asylia Diagnostics headquartered in United States, North America, operates in the Biotechnology, Artificial Intelligence (AI), Life Science, Health Care, Precision Medicine sector. The company focuses on Biotechnology and has secured $22.0M in funding across 20 round(s). With a team of 1-10 employees, Asylia Diagnostics is actively contributing to advancements in Biotechnology. Their latest funding round, Seed Round - Asylia Diagnostics, raised $1.1M. Discover more about their projects, partnerships, and impact on our platform.